Special scan could Fine-Tune breast cancer drug dose
NCT ID NCT04174352
Summary
This small, early-phase study is testing a new approach for patients whose metastatic breast cancer has become resistant to standard hormone therapy due to a specific gene change (ESR1 mutation). Researchers will use a special imaging scan (FES-PET/CT) to see how well the drug tamoxifen is blocking cancer cells in real time. The goal is to see if this scan can help doctors find a more effective, personalized dose of tamoxifen for these patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER+ BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wisconsin Oncology Network (WONIX) sites
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.